Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 2Thyroid Neoplasms 1Primary Breast Cancer 1Parkinson Disease 1Malignancy of Thyroid Nodules 1

Interventions

lutetium Lu 177 dotatate 34Everolimus 33lanreotide 13gallium Ga 68 dotatate 13Temozolomide 13Magnetic Resonance Spectroscopy 13Nivolumab 12pembrolizumab 11Octreotide 11Capecitabine 11177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9surufatinib 8Sunitinib 8Specimen Handling 7Carboplatin 7pasireotide 6amino-acid, glucose, and electrolyte solution 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Lutetium-177 5Ipilimumab 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5Bevacizumab 5telotristat ethyl 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neuroendocrine Tumors × Iodine-123 × Clear all
NCT04510311 2025-01-10

Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors

University of Michigan Rogel Cancer Center

Phase EARLY_PHASE1 Completed
32 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01931488 2013-08-29

124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.

Tel-Aviv Sourasky Medical Center

Phase 2 Unknown
40 enrolled
EndocrineNET

Parkinson Disease, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡